Elite Appoints Chris C. Dick to the Position of Vice President, Business
Development

NORTHVALE, N.J. (October 31, 2002) - Chris C. Dick has been appointed to the
position of Vice President of Business Development for Elite Laboratories, Inc.,
a wholly owned subsidiary of Elite Pharmaceuticals, Inc (Amex: ELI) effective
November 1, 2002.  Mr. Dick will direct licensing and business development
activities for Elite's products and technology systems.

Mr. Dick joins Elite from Elan Drug Delivery, Inc. where he served as Director
of Business Development. While in this position he was responsible for licensing
and business development for Elan's portfolio of drug delivery technologies.
Prior to Elan, Mr. Dick led the business development activities for EnTec, a
drug delivery business unit within FMC's Pharmaceutical Division, and for FMC's
pharmaceutical functional coatings product line. Mr. Dick held various other
business and technical positions at FMC prior to joining FMC's Pharmaceutical
Division. Mr. Dick received an M.B.A. from Stern School of Business, New York
University and an M.S. and B.S. in Chemical Engineering from Cornell University.

"We are very pleased to have someone with Chris' business development and
licensing experience join Elite," said Dr. Atul Mehta, President and CEO of
Elite. "He will complement the extensive experience and talent we have in the
other parts of the business."

Elite specializes in the development of delayed release, sustained release,
targeted release, pulse release and other oral controlled release systems. Elite
has over fifteen products under development in the therapeutic areas that
include cardiovascular, diabetes, arthritis, pain, neurology, allergy and
infection. Some of these products are being developed in collaboration with
other pharmaceutical companies. Elite has been issued three patents and
additional patent applications have been filed. Elite has also established a FDA
and DEA registered facility in Northvale, NJ.

This release contains forward-looking statements which involve known and unknown
risks, delays, uncertainties and other factors not under the Company's control,
which may cause actual results, performance or achievements of the Company to be
materially different from the results, performance or other expectations implied
by these forward-looking statements. These factors include results of current or
pending research and development activities, actions by the FDA and other
regulatory authorities, and those factors detailed in the Company's filings with
the Securities and Exchange Commission such as 10K, 10Q and 8K reports.

FOR FURTHER INFORMATION, CONTACT:
Jonathan Fassberg of The Trout Group, Investor Relations of Elite
Pharmaceuticals, Inc.
Phone: 212-477-9007  Ext. 16
Website: http://www.elitepharma.com

                                      -38-


SOURCE:  Elite Pharmaceuticals, Inc.


                                      -39-